Koers OUTLOOK THERAPEUTICS, INC. Nasdaq
Aandelen
US69012T1079
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 204K 189K | Omzet 2025 * | 11,85 mln. 11,02 mln. | Marktkapitalisatie | 200 mln. 186 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -72 mln. -66,91 mln. | Nettowinst (verlies) 2025 * | -62 mln. -57,62 mln. | EV/omzet 2024 * | 984 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 16,9 x |
K/w-verhouding 2024 * |
-2,58
x | K/w-verhouding 2025 * |
-3,69
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 61,15% |
Recentste transcriptie over OUTLOOK THERAPEUTICS, INC.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
C. Trenary
CEO | Chief Executive Officer | 66 | 07-07-21 |
Lawrence Kenyon
DFI | Director of Finance/CFO | 58 | 15-09-15 |
Surendra Sharma
CTO | Chief Tech/Sci/R&D Officer | - | 19-01-23 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Randy Thurman
CHM | Chairman | 74 | 13-04-18 |
Kurt Hilzinger
BRD | Director/Board Member | 63 | 11-12-15 |
C. Trenary
CEO | Chief Executive Officer | 66 | 07-07-21 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+25,69% | 48,09 mld. | |
+46,90% | 40,62 mld. | |
-3,46% | 40,43 mld. | |
-6,20% | 28,36 mld. | |
+9,17% | 24,89 mld. | |
-20,42% | 19,01 mld. | |
+28,07% | 12,09 mld. | |
+0,17% | 11,88 mld. | |
-1,24% | 11,8 mld. |